CRISPR Therapeutics for Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder with a prevalence of approximately 1 in 3500–5000 males. DMD manifests as childhood-onset muscle degeneration, followed by loss of ambulation, cardiomyopathy, and death in early adulthood due to a lack of functional dy...
Main Authors: | Esra Erkut, Toshifumi Yokota |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/3/1832 |
Similar Items
-
Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies
by: Elisabeth Le Rumeur
Published: (2015-07-01) -
Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy
by: Cedric Happi Mbakam, et al.
Published: (2022-03-01) -
A Decade of Progress in Gene Targeted Therapeutic Strategies in Duchenne Muscular Dystrophy: A Systematic Review
by: Lam Chung Liang, et al.
Published: (2022-03-01) -
Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges
by: Yusuke Echigoya, et al.
Published: (2018-12-01) -
Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy
by: Alberto Malerba, et al.
Published: (2012-01-01)